{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T05:35:52Z","timestamp":1791005752933,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P01AG036694"],"award-info":[{"award-number":["P01AG036694"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1K23AG053422-01"],"award-info":[{"award-number":["1K23AG053422-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AG024904"],"award-info":[{"award-number":["U01 AG024904"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010969","name":"Alzheimer Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010969","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Impairment in daily functioning is a clinical hallmark of dementia. Difficulties with \u201cinstrumental activities of daily living\u201d (IADL) seem to increase gradually over the course of Alzheimer\u2019s disease (AD), before dementia onset. However, it is currently not well established how difficulties develop along the preclinical and prodromal stages of AD. We aimed to investigate the trajectories of decline in IADL performance, as reported by a study partner, along the early stages of AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In a longitudinal multicenter study, combining data from community-based and memory clinic cohorts, we included 1555 individuals (mean age 72.5\u2009\u00b1\u20097.8\u2009years; 50% female) based on availability of amyloid biomarkers, longitudinal IADL data, and clinical information at baseline. Median follow-up duration was 2.1\u2009years. All amyloid-positive participants (<jats:italic>n<\/jats:italic>\u2009=\u2009982) were classified into the National Institute on Aging\u2013Alzheimer\u2019s Association (NIA-AA) clinical stages ranging from preclinical AD (1) to overt dementia (4+). Cognitively normal amyloid-negative individuals (<jats:italic>n<\/jats:italic>\u2009=\u2009573) served as a comparison group. The total scores of three study-partner reported IADL questionnaires were standardized.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The rate of decline in cognitively normal (stage 1) individuals with and without abnormal amyloid did not differ (<jats:italic>p<\/jats:italic>\u2009=\u2009.453). However, from stage 2 onwards, decline was significantly faster in individuals on the AD continuum (<jats:italic>B [95%CI]<\/jats:italic>\u2009=\u2009\u2212\u20090.32 [\u2212\u20090.55, \u2212\u20090.09],<jats:italic>p<\/jats:italic>\u2009=\u2009.007). The rate of decline increased with each successive stage: one standard deviation (SD) unit per year in stage 3 (\u2212\u20091.06 [\u2212\u20091.27, \u2212\u20090.85],<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001) and nearly two SD units per year in stage 4+ (1.93 [\u2212\u20092.19, \u2212\u20091.67],<jats:italic>p<\/jats:italic>\u2009&lt;\u2009.001). Overall, results were similar between community-based and memory clinic study cohorts.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our results suggest that the rate of functional decline accelerates along the AD continuum, as shown by steeper rates of decline in each successive NIA-AA clinical stage. These results imply that incremental changes in function are a meaningful measure for early disease monitoring. Combined with the low-cost assessment, this advocates the use of these functional questionnaires for capturing the effects of early AD-related cognitive decline on daily life.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13195-020-00706-2","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T21:02:43Z","timestamp":1604005363000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Decline in cognitively complex everyday activities accelerates along the Alzheimer\u2019s disease continuum"],"prefix":"10.1186","volume":"12","author":[{"name":"for the Alzheimer Disease Neuroimaging Initiative, National Alzheimer\u2019s Coordinating Center, the Harvard Aging Brain Study, the Alzheimer Dementia Cohort","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5708-4925","authenticated-orcid":false,"given":"Mark A.","family":"Dubbelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roos J.","family":"Jutten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah E.","family":"Tomaszewski Farias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca E.","family":"Amariglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel F.","family":"Buckley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter Jelle","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorene M.","family":"Rentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Properzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Gatchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte E.","family":"Teunissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart N. M.","family":"Van Berckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"Van der Flier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa A.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn V.","family":"Papp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Scheltens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gad A.","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sietske A. M.","family":"Sikkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"issue":"4","key":"706_CR1","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"706_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jalz.2014.01.001","volume":"10","author":"F Jessen","year":"2014","unstructured":"Jessen F, Amariglio RE, Van Boxtel M, Breteler MMB, Ceccaldi M, Ch\u00e9telat G, et al. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer\u2019s disease. Alzheimers Dement. 2014;10(6):844\u201352.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"706_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.jalz.2018.10.003","volume":"15","author":"RER Slot","year":"2019","unstructured":"Slot RER, Sikkes SAM, Berkhof J, Brodaty H, Buckley R, Cavedo E, et al. Subjective cognitive decline and rates of incident Alzheimer\u2019s disease and non-Alzheimer\u2019s disease dementia. Alzheimers Dement. 2019;15(3):465\u201376.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"706_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ana.21509","volume":"64","author":"H Amieva","year":"2008","unstructured":"Amieva H, Le Goff M, Millet X, Orgogozo JM, Peres K, Barberger-Gateau P, et al. Prodromal Alzheimer\u2019s disease: successive emergence of the clinical symptoms. Ann Neurol. 2008;64(5):492\u20138.","journal-title":"Ann Neurol"},{"issue":"1","key":"706_CR5","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1532-5415.2007.01499.x","volume":"56","author":"K Peres","year":"2008","unstructured":"Peres K, Helmer C, Amieva H, Orgogozo JM, Rouch I, Dartigues JF, et al. Natural history of decline in instrumental activities of daily living performance over the 10 years preceding the clinical diagnosis of dementia: a prospective population-based study. J Am Geriatr Soc. 2008;56(1):37\u201344.","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"706_CR6","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270\u20139.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"706_CR7","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jalz.2010.04.005","volume":"7","author":"GA Marshall","year":"2011","unstructured":"Marshall GA, Rentz DM, Frey MT, Locascio JJ, Johnson KA, Sperling RA, et al. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer\u2019s disease. Alzheimers Dement. 2011;7(3):300\u20138.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"706_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/archneurol.2011.3152","volume":"69","author":"JC Morris","year":"2012","unstructured":"Morris JC. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia. Arch Neurol. 2012;69(6):700\u20138.","journal-title":"Arch Neurol"},{"issue":"12","key":"706_CR9","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1212\/WNL.0b013e3181b87971","volume":"73","author":"KL Triebel","year":"2009","unstructured":"Triebel KL, Martin R, Griffith HR, Marceaux J, Okonkwo OC, Harrell L, et al. Declining financial capacity in mild cognitive impairment: a 1-year longitudinal study. Neurology. 2009;73(12):928\u201334.","journal-title":"Neurology."},{"issue":"7","key":"706_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1176\/appi.ajp.2010.09050692","volume":"167","author":"TE Goldberg","year":"2010","unstructured":"Goldberg TE, Koppel J, Keehlisen L, Christen E, Dreses-Werringloer U, Conejero-Goldberg C, et al. Performance-based measures of everyday function in mild cognitive impairment. Am J Psychiatry. 2010;167(7):845\u201353.","journal-title":"Am J Psychiatry"},{"issue":"4","key":"706_CR11","first-page":"242","volume":"2","author":"GA Marshall","year":"2015","unstructured":"Marshall GA, Dekhtyar M, Bruno JM, Jethwani K, Amariglio RE, Johnson KA, et al. The Harvard Automated Phone Task: new performance-based activities of daily living tests for early Alzheimer\u2019s disease. J Prev Alzheimers Dis. 2015;2(4):242\u201353.","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"706_CR12","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.3233\/JAD-161183","volume":"57","author":"SJ Czaja","year":"2017","unstructured":"Czaja SJ, Loewenstein DA, Sabbag SA, Curiel RE, Crocco E, Harvey PD. A novel method for direct assessment of everyday competence among older adults. J Alzheimers Dis. 2017;57(4):1229\u201338.","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"706_CR13","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jalz.2015.08.001","volume":"12","author":"VJA Verlinden","year":"2016","unstructured":"Verlinden VJA, Van der Geest JN, De Bruijn RFAG, Hofman A, Koudstaal PJ, Arfan IM. Trajectories of decline in cognition and daily functioning in preclinical dementia. Alzheimers Dement. 2016;12(2):144\u201353.","journal-title":"Alzheimers Dement"},{"issue":"2","key":"706_CR14","first-page":"81","volume":"4","author":"GA Marshall","year":"2017","unstructured":"Marshall GA, Aghjayan SL, Dekhtyar M, Locascio JJ, Jethwani K, Amariglio RE, et al. Activities of daily living measured by the Harvard Automated Phone Task track with cognitive decline over time in non-demented elderly. J Prev Alzheimers Dis. 2017;4(2):81\u20136.","journal-title":"J Prev Alzheimers Dis."},{"issue":"9","key":"706_CR15","doi-asserted-by":"publisher","first-page":"853","DOI":"10.2174\/1567205011666141001120903","volume":"11","author":"GA Marshall","year":"2014","unstructured":"Marshall GA, Zoller AS, Kelly KE, Amariglio RE, Locascio JJ, Johnson KA, et al. Everyday cognition scale items that best discriminate between and predict progression from clinically normal to mild cognitive impairment. Curr Alzheimer Res. 2014;11(9):853\u201361.","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"706_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2174\/156720501205150526115003","volume":"12","author":"GA Marshall","year":"2015","unstructured":"Marshall GA, Zoller AS, Lorius N, Amariglio RE, Locascio JJ, Johnson KA, et al. Functional activities questionnaire items that best discriminate and predict progression from clinically normal to mild cognitive impairment. Curr Alzheimer Res. 2015;12(5):493\u2013502.","journal-title":"Curr Alzheimer Res"},{"issue":"8","key":"706_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2174\/156720501108140910122220","volume":"11","author":"AS Zoller","year":"2014","unstructured":"Zoller AS, Gaal IM, Royer CA, Locascio JJ, Amariglio RE, Blacker D, et al. SIST-M-IR activities of daily living items that best discriminate clinically normal elderly from those with mild cognitive impairment. Curr Alzheimer Res. 2014;11(8):785\u201391.","journal-title":"Curr Alzheimer Res"},{"key":"706_CR18","doi-asserted-by":"crossref","unstructured":"Edgar CJ, Vradenburg G, Hassenstab J. The 2018 Revised FDA guidance for early Alzheimer\u2019s disease: establishing the meaningfulness of treatment effects. J Prev Alz Dis 2019;6:223\u20137.","DOI":"10.14283\/jpad.2019.30"},{"issue":"3","key":"706_CR19","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jagp.2012.09.006","volume":"22","author":"BA Springate","year":"2014","unstructured":"Springate BA, Tremont G. Dimensions of caregiver burden in dementia: impact of demographic, mood, and care recipient variables. Am J Geriatr Psychiatry. 2014;22(3):294\u2013300.","journal-title":"Am J Geriatr Psychiatry"},{"issue":"1","key":"706_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.trci.2017.01.004","volume":"3","author":"RJ Jutten","year":"2017","unstructured":"Jutten RJ, Harrison J, de Jong FJ, Aleman A, Ritchie CW, Scheltens P, et al. A composite measure of cognitive and functional progression in Alzheimer's disease: Design of the Capturing Changes in Cognition study. Alzheimers Dement (N Y). 2017;3(1):130\u20138.","journal-title":"Alzheimers Dement (N Y)"},{"issue":"Pt B","key":"706_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.neuroimage.2015.03.069","volume":"144","author":"A Dagley","year":"2017","unstructured":"Dagley A, LaPoint M, Huijbers W, Hedden T, McLaren DG, Chatwal JP, et al. Harvard Aging Brain Study: dataset and accessibility. Neuroimage. 2017;144(Pt B):255\u20138.","journal-title":"Neuroimage"},{"issue":"3","key":"706_CR22","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jalz.2010.03.006","volume":"6","author":"PS Aisen","year":"2010","unstructured":"Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, et al. Clinical Core of the Alzheimer\u2019s Disease Neuroimaging Initiative: progress and plans. Alzheimers Dement. 2010;6(3):239\u201346.","journal-title":"Alzheimers Dement"},{"issue":"3","key":"706_CR23","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/WAD.0b013e318142774e","volume":"21","author":"DL Beekly","year":"2007","unstructured":"Beekly DL, Ramos EM, Lee WW, Deitrich WD, Jacka ME, Wu J, et al. The National Alzheimer's Coordinating Center (NACC) database: the uniform data set. Alzheimer Dis Assoc Disord. 2007;21(3):249\u201358.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"706_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.3233\/JAD-170850","volume":"62","author":"WM van der Flier","year":"2018","unstructured":"van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62(3):1091\u2013111.","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"706_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13195-018-0406-7","volume":"10","author":"E Konijnenberg","year":"2018","unstructured":"Konijnenberg E, Carter SF, Ten Kate M, den Braber A, Tomassen J, Amadi C, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. Alzheimers Res Ther. 2018;10(1):75.","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"706_CR26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s12877-018-0984-z","volume":"18","author":"N Legdeur","year":"2018","unstructured":"Legdeur N, Badissi M, Carter SF, de Crom S, van de Kreeke A, Vreeswijk R, et al. Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. BMC Geriatr. 2018;18(1):289.","journal-title":"BMC Geriatr"},{"issue":"20","key":"706_CR27","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1212\/WNL.0000000000000431","volume":"82","author":"EC Mormino","year":"2014","unstructured":"Mormino EC, Betensky RA, Hedden T, Schultz AP, Ward A, Huijbers W, et al. Amyloid and APOE epsilon4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology. 2014;82(20):1760\u20137.","journal-title":"Neurology."},{"issue":"3","key":"706_CR28","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jama.2010.2008","volume":"305","author":"CM Clark","year":"2011","unstructured":"Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275\u201383.","journal-title":"JAMA."},{"issue":"4","key":"706_CR29","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1097\/WAD.0000000000000279","volume":"32","author":"L Besser","year":"2018","unstructured":"Besser L, Kukull W, Knopman DS, Chui H, Galasko D, Weintraub S, et al. Version 3 of the National Alzheimer\u2019s Coordinating Center\u2019s Uniform Data Set. Alzheimer Dis Assoc Disord. 2018;32(4):351\u20138.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"706_CR30","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1373\/clinchem.2017.281055","volume":"64","author":"BM Tijms","year":"2018","unstructured":"Tijms BM, Willemse EAJ, Zwan MD, Mulder SD, Visser PJ, Van Berckel BNM, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-\u03b2 1\u201342 analysis results. Clin Chem. 2018;64(3):576\u201385.","journal-title":"Clin Chem"},{"key":"706_CR31","doi-asserted-by":"publisher","unstructured":"Jutten RJ, Sikkes SAM, Amariglio RE, Buckley RF, Properzi MJ, Marshall GA, Rentz DM, Johnson KA, Teunissen CE, Van Berckel BNM, Van der Flier WM, Scheltens P, Sperling RA, Papp KV. For the Alzheimer Disease Neuroimaging Initiative and National Alzheimer\u2019s Coordinating Center, the Harvard Aging Brain Study, and the Alzheimer Dementia Cohort. Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer\u2019s Disease. 2020. https:\/\/doi.org\/10.1017\/S1355617720000934 .","DOI":"10.1017\/S1355617720000934"},{"issue":"3","key":"706_CR32","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1093\/geronj\/37.3.323","volume":"37","author":"RI Pfeffer","year":"1982","unstructured":"Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37(3):323\u20139.","journal-title":"J Gerontol"},{"issue":"4","key":"706_CR33","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1037\/0894-4105.22.4.531","volume":"22","author":"ST Farias","year":"2008","unstructured":"Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The measurement of everyday cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22(4):531\u201344.","journal-title":"Neuropsychology."},{"issue":"4","key":"706_CR34","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1017\/S1355617712001609","volume":"19","author":"ST Farias","year":"2013","unstructured":"Farias ST, Park LQ, Harvey DJ, Simon C, Reed BR, Carmichael O, et al. Everyday cognition in older adults: associations with neuropsychological performance and structural brain imaging. J Int Neuropsychol Soc. 2013;19(4):430\u201341.","journal-title":"J Int Neuropsychol Soc"},{"issue":"6","key":"706_CR35","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jalz.2011.08.006","volume":"8","author":"SAM Sikkes","year":"2012","unstructured":"Sikkes SAM, de Lange-de Klerk ES, Pijnenburg YAL, Gillissen F, Romkes R, Knol DL, et al. A new informant-based questionnaire for instrumental activities of daily living in dementia. Alzheimers Dement. 2012;8(6):536\u201343.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"706_CR36","first-page":"e12021","volume":"12","author":"MA Dubbelman","year":"2020","unstructured":"Dubbelman MA, Verrijp M, Facal D, Sanchez-Benavides G, Brown LJE, van der Flier WM, et al. The influence of diversity on the measurement of functional impairment: an international validation of the Amsterdam IADL Questionnaire in eight countries. Alzheimers Dement (Amst). 2020;12(1):e12021.","journal-title":"Alzheimers Dement (Amst)"},{"key":"706_CR37","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.dadm.2017.03.002","volume":"8","author":"RJ Jutten","year":"2017","unstructured":"Jutten RJ, Peeters CFW, Leijdesdorff SMJ, Visser PJ, Maier AB, Terwee CB, et al. Detecting functional decline from normal aging to dementia: development and validation of a short version of the Amsterdam IADL Questionnaire. Alzheimers Dement (Amst). 2017;8:26\u201335.","journal-title":"Alzheimers Dement (Amst)."},{"issue":"10","key":"706_CR38","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/j.jalz.2014.10.006","volume":"11","author":"N Koster","year":"2015","unstructured":"Koster N, Knol DL, Uitdehaag BM, Scheltens P, Sikkes SAM. The sensitivity to change over time of the Amsterdam IADL Questionnaire((c)). Alzheimers Dement. 2015;11(10):1231\u201340.","journal-title":"Alzheimers Dement"},{"issue":"1","key":"706_CR39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000346277","volume":"41","author":"SAM Sikkes","year":"2013","unstructured":"Sikkes SAM, Knol DL, Pijnenburg YAL, de Lange-de Klerk ES, Uitdehaag BM, Scheltens P. Validation of the Amsterdam IADL Questionnaire(c), a new tool to measure instrumental activities of daily living in dementia. Neuroepidemiology. 2013;41(1):35\u201341.","journal-title":"Neuroepidemiology."},{"issue":"4","key":"706_CR40","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/0891988713509139","volume":"26","author":"SAM Sikkes","year":"2013","unstructured":"Sikkes SAM, Pijnenburg YAL, Knol DL, de Lange-de Klerk ES, Scheltens P, Uitdehaag BM. Assessment of instrumental activities of daily living in dementia: diagnostic value of the Amsterdam Instrumental Activities of Daily Living Questionnaire. J Geriatr Psychiatry Neurol. 2013;26(4):244\u201350.","journal-title":"J Geriatr Psychiatry Neurol"},{"issue":"1","key":"706_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v067.i01","volume":"67","author":"D Bates","year":"2015","unstructured":"Bates D, Machler M, Bolker BM, Walker SC. Fitting linear mixed-effects models using lme4. J Stat Softw. 2015;67(1):1\u201348.","journal-title":"J Stat Softw"},{"key":"706_CR42","volume-title":"R: A language and environment for statistical computing. 4.0.2 ed","author":"R Core Team","year":"2020","unstructured":"R Core Team. R: A language and environment for statistical computing. 4.0.2 ed 2020."},{"key":"706_CR43","volume-title":"Stata Statistical Software: Release 14","author":"StataCorp","year":"2015","unstructured":"StataCorp. Stata Statistical Software: Release 14. 14th ed. College Station: StataCorp LP; 2015.","edition":"14"},{"issue":"10043","key":"706_CR44","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/S0140-6736(15)01124-1","volume":"388","author":"P Scheltens","year":"2016","unstructured":"Scheltens P, Blennow K, Breteler MMB, De Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016;388(10043):505\u201317.","journal-title":"Lancet"},{"key":"706_CR45","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed., text rev. ed. Washington, DC: American Psychiatric Association; 2000."},{"issue":"5","key":"706_CR46","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2217\/nmt.12.55","volume":"2","author":"GA Marshall","year":"2012","unstructured":"Marshall GA, Amariglio RE, Sperling RA, Rentz DM. Activities of daily living: where do they fit in the diagnosis of Alzheimer\u2019s disease? Neurodegener Dis Manag. 2012;2(5):483\u201391.","journal-title":"Neurodegener Dis Manag."},{"issue":"4","key":"706_CR47","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1037\/a0034069","volume":"28","author":"ST Farias","year":"2013","unstructured":"Farias ST, Chou E, Harvey DJ, Mungas D, Reed B, DeCarli C, et al. Longitudinal trajectories of everyday function by diagnostic status. Psychol Aging. 2013;28(4):1070\u20135.","journal-title":"Psychol Aging"},{"issue":"12","key":"706_CR48","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1111\/j.1532-5415.2011.03732.x","volume":"59","author":"SAM Sikkes","year":"2011","unstructured":"Sikkes SAM, Visser PJ, Knol DL, de Lange-de Klerk ES, Tsolaki M, Frisoni GB, et al. Do instrumental activities of daily living predict dementia at 1- and 2-year follow-up? Findings from the Development of Screening guidelines and diagnostic Criteria for Predementia Alzheimer\u2019s disease study. J Am Geriatr Soc. 2011;59(12):2273\u201381.","journal-title":"J Am Geriatr Soc"},{"key":"706_CR49","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.trci.2018.01.003","volume":"4","author":"S Weintraub","year":"2018","unstructured":"Weintraub S, Carrillo MC, Farias ST, Goldberg TE, Hendrix JA, Jaeger J, et al. Measuring cognition and function in the preclinical stage of Alzheimer\u2019s disease. Alzheimers Dement (N Y). 2018;4:64\u201375.","journal-title":"Alzheimers Dement (N Y)."},{"issue":"6","key":"706_CR50","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.jalz.2014.07.158","volume":"10","author":"PJ Snyder","year":"2014","unstructured":"Snyder PJ, Kahle-Wrobleski K, Brannan S, Miller DS, Schindler RJ, DeSanti S, et al. Assessing cognition and function in Alzheimer\u2019s disease clinical trials: do we have the right tools? Alzheimers Dement. 2014;10(6):853\u201360.","journal-title":"Alzheimers Dement"},{"issue":"6","key":"706_CR51","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/alzrt222","volume":"5","author":"DM Rentz","year":"2013","unstructured":"Rentz DM, Parra Rodriguez MA, Amariglio R, Stern Y, Sperling R, Ferris S. Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer\u2019s disease: a selective review. Alzheimers Res Ther. 2013;5(6):58.","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"706_CR52","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jalz.2016.06.2365","volume":"13","author":"M Mortamais","year":"2017","unstructured":"Mortamais M, Ash JA, Harrison J, Kaye J, Kramer J, Randolph C, et al. Detecting cognitive changes in preclinical Alzheimer\u2019s disease: a review of its feasibility. Alzheimers Dement. 2017;13(4):468\u201392.","journal-title":"Alzheimers Dement"},{"issue":"4","key":"706_CR53","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1136\/jnnp-2013-305078","volume":"85","author":"T Mura","year":"2014","unstructured":"Mura T, Proust-Lima C, Jacqmin-Gadda H, Akbaraly TN, Touchon J, Dubois B, et al. Measuring cognitive change in subjects with prodromal Alzheimer\u2019s disease. J Neurol Neurosurg Psychiatry. 2014;85(4):363\u201370.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"706_CR54","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2217\/nmt.14.24","volume":"4","author":"SAM Sikkes","year":"2014","unstructured":"Sikkes SAM, De Rotrou J. A qualitative review of instrumental activities of daily living in dementia: what\u2019s cooking? Neurodegener Dis Manag. 2014;4(5):393\u2013400.","journal-title":"Neurodegener Dis Manag"},{"issue":"7","key":"706_CR55","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jalz.2019.04.001","volume":"15","author":"L Vermunt","year":"2019","unstructured":"Vermunt L, Sikkes SAM, van den Hout A, Handels R, Bos I, van der Flier WM, et al. Duration of preclinical, prodromal, and dementia stages of Alzheimer\u2019s disease in relation to age, sex, and APOE genotype. Alzheimers Dement. 2019;15(7):888\u201398.","journal-title":"Alzheimers Dement"},{"issue":"10","key":"706_CR56","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1001\/jamaneurol.2019.1971","volume":"76","author":"CR Jack Jr","year":"2019","unstructured":"Jack CR Jr, Therneau TM, Weigand SD, Wiste HJ, Knopman DS, Vemuri P, et al. Prevalence of biologically vs clinically defined Alzheimer spectrum entities using the National Institute on Aging-Alzheimer\u2019s Association research framework. JAMA Neurol. 2019;76(10):1174\u201383.","journal-title":"JAMA Neurol"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00706-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13195-020-00706-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00706-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T17:06:26Z","timestamp":1669395986000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00706-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["706"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00706-2","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"23 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The studies of which we used data in this study have been approved by their institutions\u2019 respective ethical review boards. All subjects provided written informed consent for the use of their data for research purposes, in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MAD, RJJ, SETF, REA, RFB, PJV, DMR, KAJ, MJP, AS, ND, JRG, BNMB, and RAS report no disclosures relevant to this manuscript. SAMS is supported by grants from JPND and Zon-MW and has provided consultancy services in the past 2\u2009years for Nutricia and Takeda. All funds were paid to her institution. GAM has received research salary support from Eisai Inc., Eli Lilly and Company, Janssen Alzheimer Immunotherapy, Novartis, and Genentech. Additionally, GAM has served as a consultant for Grifols Shared Services North America, Inc., Eisai Inc., and Pfizer. WMF holds the Pasman chair. CET received grants from the European Commission, the Dutch Research Council (ZonMW), Association of Frontotemporal Dementia\/Alzheimer\u2019s Drug Discovery Foundation, The Weston Brain Institute, Alzheimer Nederland. CET has functioned in advisory boards of Roche, received non-financial support in the form of research consumables from ADxNeurosciences and Euroimmun, performed contract research, or received grants from Probiodrug, Biogen, Esai, Toyama, Janssen prevention center, Boehringer, AxonNeurosciences, EIP farma, PeopleBio, and Roche. KVP has served as a paid consultant for Biogen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}